Objective: An increasing number of patients with advanced pancreatic or biliary tract cancer who progress after a gemcitabine-containing regimen are candidates for further chemotherapy. We therefore evaluated a fully oral regimen of capecitabine and celecoxib (CapCel) as second-line treatment in these patients. Methods: Thirty-five patients with documented progressive disease after first-line treatment were enrolled. Capecitabine was administered at a dose of 1,000 mg/m2b.i.d. for 2 consecutive weeks followed by 1 week of rest; celecoxib was given continuously at 200 mg b.i.d. Progression-free survival at 3 months was the primary study endpoint. Results: The CapCel combination was associated with an overall response rate of 9% and median survival duration of 19 weeks. Sixty percent of patients were free from progression 3 months after the start of treatment. Multivariate analysis identified a positive clinical benefit response and a decline in CA 19.9 serum levels >25% compared with baseline levels as independent predictors of prolonged survival. The treatment protocol was well tolerated with negligible hematological toxicity. The most common grade 3 non-hematological toxicities were hypertransaminasemia, diarrhea and asthenia. Conclusions: The CapCel combination is a safe treatment option with moderate activity in patients with pancreatic/biliary tract cancer after failure of a previous gemcitabine- containing regimen.

Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers / Pino, M. S.; Milella, M.; Gelibter, A.; Sperduti, I.; De Marco, S.; Nuzzo, C.; Bria, E.; Carpanese, Livio; Ruggeri, E. M.; Carlini, P.; Cognetti, F.. - In: ONCOLOGY. - ISSN 0030-2414. - 76:4(2009), pp. 254-261. [10.1159/000205388]

Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers

Pino M. S.;Milella M.;Gelibter A.;Sperduti I.;CARPANESE, livio;Cognetti F.
2009

Abstract

Objective: An increasing number of patients with advanced pancreatic or biliary tract cancer who progress after a gemcitabine-containing regimen are candidates for further chemotherapy. We therefore evaluated a fully oral regimen of capecitabine and celecoxib (CapCel) as second-line treatment in these patients. Methods: Thirty-five patients with documented progressive disease after first-line treatment were enrolled. Capecitabine was administered at a dose of 1,000 mg/m2b.i.d. for 2 consecutive weeks followed by 1 week of rest; celecoxib was given continuously at 200 mg b.i.d. Progression-free survival at 3 months was the primary study endpoint. Results: The CapCel combination was associated with an overall response rate of 9% and median survival duration of 19 weeks. Sixty percent of patients were free from progression 3 months after the start of treatment. Multivariate analysis identified a positive clinical benefit response and a decline in CA 19.9 serum levels >25% compared with baseline levels as independent predictors of prolonged survival. The treatment protocol was well tolerated with negligible hematological toxicity. The most common grade 3 non-hematological toxicities were hypertransaminasemia, diarrhea and asthenia. Conclusions: The CapCel combination is a safe treatment option with moderate activity in patients with pancreatic/biliary tract cancer after failure of a previous gemcitabine- containing regimen.
2009
advanced pancreatic carcinoma; biliary tract cancer; capecitabine; celecoxib; oral chemotherapy; adenocarcinoma; adult; aged; antineoplastic combined chemotherapy protocols; biliary tract neoplasms; capecitabine; carcinoma, pancreatic ductal; celecoxib; deoxycytidine; female; fluorouracil; humans; male; middle aged; pancreatic neoplasms; prospective studies; pyrazoles; sulfonamides
01 Pubblicazione su rivista::01a Articolo in rivista
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers / Pino, M. S.; Milella, M.; Gelibter, A.; Sperduti, I.; De Marco, S.; Nuzzo, C.; Bria, E.; Carpanese, Livio; Ruggeri, E. M.; Carlini, P.; Cognetti, F.. - In: ONCOLOGY. - ISSN 0030-2414. - 76:4(2009), pp. 254-261. [10.1159/000205388]
File allegati a questo prodotto
File Dimensione Formato  
Pino_Capecitabine_2009.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 152.95 kB
Formato Adobe PDF
152.95 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1311279
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 42
  • ???jsp.display-item.citation.isi??? 40
social impact